Related references
Note: Only part of the references are listed.ENIGMA-DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross-diagnostic psychiatric research
Peter Kochunov et al.
HUMAN BRAIN MAPPING (2022)
A White Matter Connection of Schizophrenia and Alzheimer's Disease
Peter Kochunov et al.
SCHIZOPHRENIA BULLETIN (2021)
ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries
Paul M. Thompson et al.
TRANSLATIONAL PSYCHIATRY (2020)
Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3
Artemis Zavaliangos-Petropulu et al.
FRONTIERS IN NEUROINFORMATICS (2019)
Toward High Reproducibility and Accountable Heterogeneity in Schizophrenia Research
Peter Kochunov et al.
JAMA PSYCHIATRY (2019)
White Matter in Schizophrenia Treatment Resistance
Peter Kochunov et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group
S. Kelly et al.
MOLECULAR PSYCHIATRY (2018)
Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium
Theo G. M. van Erp et al.
BIOLOGICAL PSYCHIATRY (2018)
The UK Biobank resource with deep phenotyping and genomic data
Clare Bycroft et al.
NATURE (2018)
Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group
L. Schmaal et al.
MOLECULAR PSYCHIATRY (2017)
Cognitive decline in Parkinson disease
Dag Aarsland et al.
NATURE REVIEWS NEUROLOGY (2017)
ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwide
Paul M. Thompson et al.
NEUROIMAGE (2017)
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
Michael W. Weiner et al.
ALZHEIMERS & DEMENTIA (2017)
Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium (vol 21, pg 547, 2016)
T. G. M. van Erp et al.
MOLECULAR PSYCHIATRY (2016)
Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group
L. Schmaal et al.
MOLECULAR PSYCHIATRY (2016)
Diffusion-weighted imaging uncovers likely sources of processing-speed deficits in schizophrenia
Peter Kochunov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia A Network Meta-analysis
Myrto T. Samara et al.
JAMA PSYCHIATRY (2016)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner et al.
Alzheimers & Dementia (2015)
Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age
J. Kulkarni et al.
MOLECULAR PSYCHIATRY (2015)
Neurodevelopmental and Neurodegenerative Models of Schizophrenia: White Matter at the Center Stage
Peter Kochunov et al.
SCHIZOPHRENIA BULLETIN (2014)
New Models for Large Prospective Studies: Is There a Better Way?
Teri A. Manolio et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)
Cerebrovascular lesions induce transient β-amyloid deposition
Monica Garcia-Alloza et al.
BRAIN (2011)
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors
Raj N. Kalaria et al.
LANCET NEUROLOGY (2008)
Aggregation of vascular risk factors and risk of incident Alzheimer disease
JA Luchsinger et al.
NEUROLOGY (2005)
Stroke and the risk of Alzheimer disease
LS Honig et al.
ARCHIVES OF NEUROLOGY (2003)
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations
RE Hoffman et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
U Heresco-Levy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Share Paper
